Pursuing therapeutic success in Crohn’s disease: A matter of definition, tools and longterm outcomes

Loredana Goran,1,2 Monica State,2,3 Ana Maria Negreanu2 and Lucian Negreanu1,2

Abstract
Management of Crohn’s disease (CD) based on symptom control is a tale of the past as new treatment strategies aim toward a “treat to target” concept and to a patient-tailored approach. Defining treatment goals and assessing therapeutic success have been in the center of IBD research in the past years. Clinical remission and mucosal healing are well-established treatment goals by current recommendations, although prospective data is required to determine whether achieving these targets is enough to alter disease natural course. Furthermore, there is no standard in assessing therapeutic success. Low relapse and hospitalization rates, as well as a low need of surgery are indicators of a successful treatment. Close monitoring is part of the new therapeutic strategy. Monitoring tools are numerous, comprising clinical, biological, endoscopic and imaging scores or parameters but are far from being perfect. The traditional strategy of managing CD patients based on clinical symptoms and response to treatment did not improve the long-term outcomes. Clinical activity scores are frequently used in clinical trials and daily practice, but their use alone is not an accurate measure of inflammation. Endoscopic remission is associated with a lower risk of complications and a better long-term prognostic. Several guidelines include recommendations regarding surveillance endoscopy, but there is an open debate regarding the follow-up intervals. Cross-sectional imaging techniques play a complementary role in assessing transmural inflammation and in identifying extra-intestinal complications of CD and should be used in conjunction with endoscopy. Therapeutic drug monitoring is essential in assessing loss of response and making therapeutic decisions, although firm recommendations are not implemented into daily practice. Extraintestinal manifestations are often disregarded when discussing monitoring protocols. There is no current guideline indication for extraintestinal manifestations monitoring during remission periods.

Keywords
activity scores, Crohn’s disease, extraintestinal manifestations, inflammatory bowel disease, monitoring, therapeutic drug monitoring, therapeutic success

Date received: 1 June 2020; accepted: 10 September 2020

Core tip
Crohn’s disease remains a debilitating disease, far from being controlled in a satisfactory manner. At the present, there is no standard in assessing therapeutic success. Clinical remission and mucosal healing are well established treatment goals, but it’s uncertain if these targets are enough to alter disease course. Monitoring tools are numerous, comprising clinical, biological, endoscopic and imaging scores

1Gastroenterology Department, Emergency University Hospital, Bucharest, Romania
2Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
3Gastroenterology Department, Colentina Clinical Hospital Bucharest, Bucharest, Romania

Corresponding author:
Monica State, Gastroenterology Department, Colentina Clinical Hospital Bucharest, Stefan cel Mare Boulevard 19-21, Bucharest 020125, Romania.
Email: monicastate4@gmail.com
European Journal of Inflammation

or parameters but are far from being perfect. The ability to predict the course of disease in any given individual or group of individuals is yet to be achieved. Until then, close monitoring of patients and tailored therapies remain the best approach.

Introduction

Crohn’s disease (CD) is a chronic, relapsing, inflammatory disease that can affect any part of the gastrointestinal tract, with terminal ileum being the most common site of disease localization. CD diagnosis is established on clinical, biochemical, endoscopic, imagistic, and histologic features.1

Disease natural course often encompasses complications and up to half of patients need surgery within 10 years of diagnosis.2 Treatment armamentarium widely extended over the past decade but the proportion of patients not entering or not maintaining remission remains high.3 The ability to predict the course of disease in any given individual or group of individuals is yet to be achieved. Until then, close monitoring of patients and tailored therapies remain the best approach.

Monitoring tools are numerous, comprising clinical, biological, endoscopic, and imaging scores or parameters but are far from being perfect.

A discordance between symptoms and endoscopic findings can be frequently encountered in patients with CD. Patients in clinical remission can have severe endoscopic activity that ultimately leads to complications and altered quality of life.4 Strategies used to control CD have changed over time from symptom control to inflammation control, mucosal healing (MH) being the new treatment target. MH is correlated with fewer surgical interventions and an improved long-term outcome of CD patients.5 Although mucosal healing is a well-established treatment goal by current recommendations, prospective data is required to determine whether achieving it is enough to alter disease natural course. Furthermore, there is no validated definition of mucosal healing in CD.

Predictors of treatment response, risk factors for poor disease outcome, surgery and early post-operative recurrence are currently being identified, but disease course remains unpredictable and a challenge for medical management. For example, young age at diagnosis, extensive small-bowel disease, perianal disease, use of corticosteroids, and smoking correlate with poor disease outcome6 and need for surgery.7 There is increasing evidence that early treatment with disease-modifying agents, such as biologic agents, may lead to better disease control and prevention of disease progression thus protecting against irreversible damage and restoration of normal quality of life.8

Objective measures of subclinical inflammation could anticipate a clinical relapse and help tailor therapeutic management, but there is a growing need to replace invasive tests by non-invasive markers. Available tools and time intervals for monitoring Crohn’s disease are available in Table 1.

Clinical monitoring

The traditional strategy of managing CD patients based on clinical symptoms and response to treatment did not improve the long-term outcomes. The new concept of “treat to target” highlights the need of objective tools to assess disease activity. The most common scoring systems used to evaluate clinical disease activity are the Crohn’s Disease Activity Index (CDAI), the Harvey-Bradshaw Index (HBI), and the Inflammatory Bowel Disease Questionnaire (IBDQ). The HBI might be easier to use and correlates well, but not perfect with the CDAI results in assessing disease’s activity.13,14 A notable drawback of these scores is the subjectivity of some items, for example “general well-being” or “pain severity” appreciation. Although these scores are frequently used in clinical trials and daily practice, their use alone is not an accurate measure of inflammation.15

Recurrence after resection in CD is frequent, therefore post-operative monitoring patients should be performed regularly.16 Although there are studies that suggest that the CDAI score can be used as an assessment tool for recurrence17 other studies show a poor correlation between CDAI and endoscopic recurrence 1 year after intestinal resection.18 In a post-operative setting, CDAI might be useful, but ileocolonoscopy remains the gold standard.

The need for more accurate clinical disease activity indices that can provide a good correlation with the endoscopic activity lead to development of a new score, the HBI-PRO score, that incorporates the HBI, C-reactive protein (CRP) and the patient and clinician owns perception of disease activity.19 This new score better estimates the endoscopic activity of ileocolonic CD.
In our opinion, the superiority of a certain monitoring tool is not yet clear, but the use of clinical activity scores and not physician global assessment of symptoms for decision making is mandatory.

Another key point refers to frequency of patient follow-up. Papay et al. proposed an adaptation of monitoring strategies for symptomatic, asymptomatic and post-operative patients. Patients with indolent and stable disease in remission may only be followed up every 12 months, while post-operative patients should be evaluated every 3 months, given the high rates of disease recurrence.20 This approach could be an acceptable compromise considering symptoms might not correlate well with disease activity. We consider that a proactive routine use of biomarkers every three months even in asymptomatic patients is the best approach.

**Laboratory monitoring**

Identifying a biomarker that can reflect the presence of active inflammation in IBD patients has been the objective of many studies and remains an unmet need. Data gathered so far support the use of CRP and the heat-stable granulocyte-derived protein, fecal calprotectin (FC).

CRP, although is inexpensive, is not a specific marker of intestinal inflammation and not all patients with active disease have high values of the CRP.21 Multiple studies have shown a good correlation between the level of CRP and endoscopic activity of the disease.22,23 Also, it was observed that the CRP level rises between 4 and 6 months before clinical relapse, thereby it can be used proactively in order to prevent the relapse.24 Another advantage would be that it can be used to monitor patients on biologic therapy, as early return to baseline of the CRP level correlates with a sustained long-term response.25

FC, an inflammatory protein found in the cytosol of human neutrophils, can be used as a marker for monitoring CD. Many studies showed that there is a good correlation between the level of FC and the Crohn’s disease endoscopic index of severity (CDEIS) and the Simple Endoscopic Score for Crohn’s disease (SES-CD),26–28 reflecting intestinal inflammation by non-invasive sampling. FC can also be used to identify patients with higher risk of relapse, as numerous studies reported a good sensitivity and specificity in predicting relapses29,30 and as well as in monitoring response after biologic therapy has been stopped.31

The main limitations of CRP and stool biomarkers in monitoring CD is that their non-specificity for IBD and the lack of validated thresholds for active disease and remission.19 A meta-analysis of 19 studies revealed that fecal calprotectin has a higher sensitivity in assessing endoscopic active disease compared to CRP.17 Regarding postoperative follow-up, it appears that FC is more consistent with recurrence than CRP.32

The CALM study revealed that treatment management based on both clinical symptoms and

| Table 1. Available tools and time intervals for monitoring Crohn’s disease. |
|-----------------------------|-----------------------------|
| **Monitoring tools** | **Time intervals** |
| Laboratory tests | |
| CRP | • 12 weeks after initiation of therapy  |
| | • every 3 to 6 months in asymptomatic patients |
| Faecal calprotectin | • after initiation of therapy (unclear time interval) |
| | • predicting relapse (unclear time interval)9 |
| | • every 4 to 6 months after surgery10 |
| Endoscopy | • 6 months after initiation of therapy  |
| | • relapse  |
| | • prior to switch of therapy11 |
| | • 6 to 12 months after surgery |
| Imaging | • 6 months after initiation of therapy |
| | • relapse |
| | • prior to switch of therapy11 |
| Therapy monitoring | TDM for antiTNF |
| | • at the end of induction for responders and non-responders |
| | • once during maintenance |
| | • secondary loss of response12 |
| Extraintestinal manifestations | Interdisciplinary monitoring of adverse events (no current recommendations) |
| | no current recommendations |
biomarkers achieved better endoscopic outcomes compared to decisions guided by symptoms alone. At the same time, the 28 IBD specialist who established the goals of the “treat to target” patient management in the STRIDE program considered the decrease of CRP and calprotectin as an adjunctive target.

Very promising biomarkers are peripheral blood miRNAs, recent data suggesting miRNAs can distinguish active IBD subtypes from each other and from healthy controls. Furthermore, miRNAs levels have been shown to vary between active and inactive Crohn’s and UC patients in both colonic tissue and serum samples.

Endoscopic monitoring

Endoscopy is the gold standard for diagnosis and evaluation of mucosal inflammation in CD. In order to have an objective tool for assessment of disease extent and severity, two endoscopic scores are being used, CDEIS and SES-CD. The Rutgeerts score is widely used for postoperative recurrence.

The importance of endoscopic monitoring is supported by various studies stating that endoscopic remission is associated with a lower risk of complications and a better long-term outcomes. At the present, there is no consensus regarding follow-up intervals for endoscopic evaluation. Available data is presented in Table 1. We consider that endoscopy should be performed to all patients at diagnosis, when there is a need for therapy changes or when a suspicion of disease progression exists (based on symptoms or biomarkers). Patients with extensive colonic involvement and long-standing disease have an increased risk of colorectal cancer compared to general population. Following a screening colonoscopy protocol is necessary in order to detect early dysplasia and cancer, as recommended by current guidelines.

Small bowel evaluation using balloon-assisted endoscopy or push enteroscopy has the disadvantage of being invasive and time-consuming methods. An alternative is capsule endoscopy (CE), a non-invasive and well tolerated technique, with a crucial role in three settings: in suspected CD, unclassified IBD (IBDU) and established CD. It can be useful in establishing diagnosis, assessing severity and disease extension.

In suspected CD, when endoscopic and imagistic results are inconclusive, CE resulted to have a higher diagnostic yield compared to computed tomography enterography (CTE) and ileocolonoscopy. In IBDU patients, CE proved to be very useful in reclassification of patients, having a high sensitivity and specificity and a negative predictive value of 94% for the absence of lesions.

When it comes to patients with established CD, a discordance between symptoms, endoscopic and imagistic findings make CE evaluation a tool useful in monitoring and management of treatment. In a retrospective study of 128 symptomatic IBD patients evaluated by CE, 61.6% of patients had a medication change and 12.8% suffered a surgical intervention. Another study involving patients with established CD revealed that for more than 50% of patients therapy changes were made based on CE findings.

For an objective assessment of CE findings, two scores were validated, the Capsule Endoscopy CD Activity Index (CECDAI) and the Lewis score. There is a correlation between the Lewis score and fecal calprotectin level, when FC is less than 100 µg/g.

We see a potential use of iterative capsule examinations especially with the new Crohn capsule in a treat to target approach.

Cross sectional imaging monitoring

Cross-sectional imaging techniques play a complementary role in assessing transmural inflammation and in identifying extra-intestinal complications of CD. Ultrasound (US), a non-invasive, low-cost and radiation-free imagistic technique, is used in examining mainly the colon and the terminal ileum, evaluating the wall thickness and stiffness, loss of stratification and the presence of complications such as strictures, fistulae or abscesses. Bowel vascularization can be evaluated by using color Doppler US or contrast-enhanced ultrasoundography (CEUS). CEUS has a high precision in identifying active disease and correlated well with MRI findings.

US can be used in monitoring CD patients as CEUS findings correlate with endoscopic severity and disease activity, having a high sensitivity and specificity in predicting active disease. Also, it has a role in assessing treatment response and efficacy and has good results in identifying postoperative recurrence.
Computed tomography enterography (CTE) is a useful tool in evaluating CD activity and severity, as well as extraluminal complications, with the benefit of distinguishing active inflammation from fibrosis. Even though it has the disadvantage of using ionizing radiation, CTE is widely available, has lower costs compared to magnetic resonance enterography (MRE) and can be used to monitor treatment response, as its results correlate well with disease activity. Additionally, it’s a very good option in emergency settings.

As CD patients usually need multiple imagistic evaluations during their lives, choosing a radiation free technique becomes relevant, especially in young patients. Considering these aspects, when available, MRE becomes the method of choice.

Both CTE and MRE offer additional information to ileocolonoscopy in evaluating disease activity, with MRE being superior to CTE in identifying intestinal strictures. In a retrospective study of 50 CD patients, MRE findings indicated the need for treatment modification in 24% of patients who had endoscopic remission defined by a SES-CD <5. MRE can be used in diagnosing small bowel inflammation and as well as a prognostic tool for relapses, therefore it has found its place in monitoring CD patients.

The recent VERSIFY reports on MRI activity using the MaRIA score in an exploratory analysis, which proved to be another objective assessment of inflammation in selected CD patients, with a good agreement between the SES-CD and MaRIA scores. We believe that this is a major breakthrough in patient’s approach, that needs to be further evaluated in additional clinical trials. The use of any of the imagistic methods depends on local expertise, availability and costs; for example, a comparison of medical services for IBD patients between Oxford (UK) and Milan (Italy) audited using the National UK audit tool, revealed that CT is more frequently used in Oxford while in Milan ultrasound is preferred.

Therapy monitoring

After starting treatment, patients are regularly evaluated. Clinical, biologic, endoscopic and imaging parameters are assessed, in order to monitor treatment efficiency and identify treatment related complications. Guidelines recommendations don’t offer firm follow-up periods. From our experience, in real-life settings, physicians adapt follow-up periods to patients’ needs and maintain a cautious attitude following short interval follow-up protocols.

Regarding treatment management, it was noticed that patients aged 65 or older are mainly treated with corticosteroids and very few are receiving anti-TNF drugs, which in turn can lead to serious adverse effects and complications. Considering these results and the fact that use of corticosteroids is associated with serious infections and low bone mineral density among other side effects, we support the use of steroid sparing agents according to current guidelines, as well as a monitoring bone density every year.

Monitoring anti-drug antibodies is not recommended on routine basis, but it’s a cost-effective strategy and it becomes very useful when patients lose response to treatment. Infliximab dosing based on therapeutic drug monitoring does not increases remission rates but it is associated with fewer flares. IFX discontinuation and intestinal surgery were significantly less frequent with therapeutic drug monitoring (TDM) and investigating loss of response resulted in change in patient management. Therapeutic drug monitoring may be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. Additionally, the combination of calprotectin and trough concentration of infliximab can guide dose adjustment and increase the chances for endoscopic response and remission. Recently a consensus has become available regarding the appropriate TDM of antiTNF agents. More data is required to establish clear recommendations regarding other biologic agents.

The proinflammatory state of IBD patients plays a significant role in the microvascular dysfunction noticed in IBD patients. Studies show that there is an increased risk of stroke, myocardial infarction and venous thromboembolism. TNF-alpha antagonists may reduce the cardiovascular risk, while corticosteroids are associated with a higher risk of cardiac events.

Another important aspect is that patients treated with anti-TNF drugs have a higher risk of melanoma and patients treated with thiopurines a higher risk of non-melanoma skin cancer. Anti-TNF therapy is associated with the occurrence of psoriasiform skin lesions, with a higher prevalence in women and sometimes there is a need to
withdraw biologic therapy.77 Considering these aspects, we consider it is important for patients to receive dermatologic counseling, be monitored for skin cancer and use adequate sunscreen.

Monitoring disease in order to adjust treatment in time to prevent progression and complications becomes a requisite when it comes to CD patients. Pallotta and colleagues developed a risk score system that evaluates disease progression and the need for changing treatment, score that needs validation, but might become the objective tool we need in managing CD.78 They identified 12 risk factors that subdivide in four risk scores predicting the need to use corticosteroids, the need to start azathioprine, anti-TNF drugs and the need of surgery.

Monitoring extraintestinal manifestations (EIM)

Up to 40% of IBD patients experience at least one EIM, which can manifest before IBD is diagnosed and be more debilitating than the intestinal disease itself.79 More common in CD patients, some EIM can be life-threatening, such as primary sclerosing cholangitis (PSC) or venous thromboembolism. Most EIMs run in parallel with intestinal disease activity, with the exception of ankylosing spondylitis and uveitis and possibly PSC and pyoderma gangrenosum (PG).80 Therefore, we suggest that EIM should be independently monitored. For example, the presence of PSC is an independent risk factor for the development of colorectal dysplasia and/or cancer in patients with IBD, leading to the recommendation for annual surveillance colonoscopies in affected patients from the time of first diagnosis of IBD.81

There is no current guideline indication for EIM monitoring in remission periods. In the authors opinion, patients already diagnosed with at least one EIM should be monitored jointly with the rheumatologist/ophthalmologist, independent of intestinal disease activity. Patient awareness of extraintestinal complications related to their disease is still an improving effort, few of them being informed about the life-threatening potential of some EIM.82 Therefore, it is of utmost importance to monitor EIM and to enhance patient education measures.

Conclusion

Over the past decade, we witnessed numerous breakthroughs in IBD research, but a standard in assessing therapeutic success is yet to be established. Clinical remission and mucosal healing remain for now the pursued treatment targets, and future prospective studies will show if this strategy is enough to alter disease course. The numerous monitoring tools, comprising clinical, biological, endoscopic and imaging scores or parameters provide help in guiding therapy, but are far from being perfect.

Author note

The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Author contributions

All authors contributed to this paper being involved in analysis and review of the literature, writing and editing the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Monica State https://orcid.org/0000-0003-4961-3476
Lucian Negreanu https://orcid.org/0000-0003-3042-0754

References

1. Van Assche G, Dignass A, Panes J et al. (2020) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. Journal of Crohn’s and Colitis 4(1): 7–27.
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF et al. (2010) The natural history of adult Crohn’s disease in population-based cohorts. The American Journal of Gastroenterology 105(2): 289–297.
3. Peyrin-Biroulet L and Lémann M (2011) Review article: Remission rates achievable by current therapies for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 33(8): 870–879.
4. Froslie KF, Jahnsen J, Moum BA et al. (2007) Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 133(2): 412–422.
5. Schnitzler F, Fidder H, Ferrante M et al. (2009) Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. *Inflammatory Bowel Diseases* 15(9): 1295–1301.

6. Dias CC, Rodrigues PP, da Costa-Pereira A et al. (2013) Clinical prognostic factors for disabling Crohn’s disease: A systematic review and meta-analysis. *World Journal of Gastroenterology* 19(24): 3866–3871.

7. Gionchetti P, Dignass A, Danese S et al. (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: Surgical management and special situations. *Journal of Crohn’s and Colitis* 11(2): 135–149.

8. Danese S, Fiorino G and and Peyrin-Biroulet L (2017) Early intervention in Crohn’s disease: Towards disease modification trials. *Gut* 66(12): 2179–2187.

9. Mumolo MG, Bertani L, Cecarelli L et al. (2018) From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. *World Journal of Gastroenterology* 24(33): 3681–3694.

10. Bjarnason I (2017) The use of fecal calprotectin in inflammatory bowel disease. *Gastroenterology & Hepatology* 13(1): 53–56.

11. Maaser C, Sturm A, Vavricka SR et al. (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *Journal of Crohn’s and Colitis* 13(2): 144–164.

12. Papamichael K, Cheifetz AS, Melmed GY et al. (2019) Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. *Clinical Gastroenterology and Hepatology* 17(9): 1655–1668.

13. Vermeire S, Schreiber S, Sandborn WJ et al. (2010) Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. *Clinical Gastroenterology and Hepatology* 8(4): 357–363.

14. Stidham RW and Cross RK (2016) Endoscopy and cross-sectional imaging for assessing Crohn’s disease activity. *Techniques in Gastrointestinal Endoscopy* 18(3): 123–130.

15. Peyrin-Biroulet L, Reinisch W, Colombel JF et al. (2014) Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. *Gut* 63(1): 88–95.

16. Olaion G, Smedh K and and Sjödahl R (1992) Natural course of Crohn’s disease after ileocolic resection: Endoscopically visualised ileal ulcers preceding symptoms. *Gut* 33(3): 331–335.

17. Walters TD, Steinhart AH, Bernstein CN et al. (2011) Validating Crohn’s disease activity indices for use in assessing postoperative recurrence. *Inflammatory Bowel Diseases* 17(7): 1547–1556.

18. Regueiro M, Kip KE, Schraut W et al. (2011) Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. *Inflammatory Bowel Diseases* 17(1): 118–126.

19. Zittan E, Kabakchiev B, Kelly OB et al. (2017) Development of the Harvey-Bradshaw index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn’s disease. *Journal of Crohn’s and Colitis* 11(5): 543–548.

20. Papa P, Ignjatovic A, Karmiris K et al. (2013) Optimising monitoring in the management of Crohn’s disease: A physician’s perspective. *Journal of Crohn’s and Colitis* 7(8): 653–669.

21. Jones J, Loftus EV Jr, Panaccione R et al. (2008) Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. *Clinical Gastroenterology and Hepatology* 6(11): 1218–1224.

22. Solem CA, Loftus EV Jr, Tremaine WJ et al. (2005) Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. *Inflammatory Bowel Diseases* 11(8): 707–712.

23. Mosli MH, Zou G, Garg SK et al. (2015) C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. *The American Journal of Gastroenterology* 110(6): 802–819.

24. Consigny Y, Modigliani R, Colombel JF et al. (2006) A simple biological score for predicting low risk of short-term relapse in Crohn’s disease. *Inflammatory Bowel Diseases* 12(7): 551–557.

25. Jürgens M, Mahachie John JM, Cleynen I et al. (2011) Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. *Clinical Gastroenterology and Hepatology* 9(5): 421–427.

26. D’Haens G, Ferrante M, Vermeire S et al. (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. *Inflammatory Bowel Diseases* 18(12): 2218–2224.

27. Sipponen T, Kärkkäinen P, Savilahti E et al. (2008) Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. *Alimentary Pharmacology & Therapeutics* 28(10): 1221–1229.

28. Sipponen T, Savilahti E, Kolho KL et al. (2008) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn’s disease activity index and endoscopic findings. *Inflammatory Bowel Diseases* 14(1): 40–46.

29. Mao R, Xiao YL, Gao X et al. (2012) Fecal calprotectin in predicting relapse of inflammatory bowel
diseases: A meta-analysis of prospective studies. *Inflammatory Bowel Diseases* 18(10): 1894–1899.

30. Naismith GD, Smith LA, Barry SJ et al. (2014) A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. *Journal of Crohn’s and Colitis* 8(9): 1022–1029.

31. Molander P, Färkkilä M, Ristimäki A et al. (2015) Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? *Journal of Crohn’s and Colitis* 9(1): 33–40.

32. Wright EK, Kamm MA, De Cruz P et al. (2015) Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. *Gastroenterology* 148(5): 938–947.

33. Colombel JF, Panaccione R, Bossuyt P et al. (2018) Effect of tight control management on Crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial. *The Lancet* 390(10114): 2779–2789.

34. Peyrin-Biroulet L, Sandborn W, Sands BE et al. (2015) Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. *The American Journal of Gastroenterology* 110(9): 1324–1338.

35. Norouzinia M, Chaleshi V, Alizadeh AHM et al. (2017) Biomarkers in inflammatory bowel diseases: Insight into diagnosis, prognosis and treatment. *Gastroenterology and Hepatology from Bed to Bench* 10(3): 155–167.

36. Mazzuoli S, Guglielmi FW, Antonelli E et al. (2013) Definition and evaluation of mucosal healing in clinical practice. *Digestive and Liver Disease* 45(12): 969–977.

37. Baert F, Moortgat L, Van Assche G et al. (2010) Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. *Gastroenterology* 138(2): 463–468.

38. M’Koma AE, Harold L, Moses HL et al. (2011) Inflammatory bowel disease-associated colorectal cancer: Proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. *International Journal of Colorectal Disease* 26(5): 533–552.

39. Luján-Sanchis M, Sanchis-Artero L, Suárez-Callop P et al. (2014) Indications of capsule endoscopy in Crohn’s disease. *Revista Espanola de Enfermedades Digestivas* 106(1): 37–44.

40. Dionisio PM, Gurudu SR, Leighton JA et al. (2010) Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: A meta-analysis. *The American Journal of Gastroenterology* 105(6): 1240–1248.

41. Monteiro S, Dias de Castro F, Boal Carvalho P et al. (2017) Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified. *World Journal of Gastrointestinal Endoscopy* 9(1): 34–40.

42. Lorenzo-Zúñiga V, de Vega VM, Doménech E et al. (2010) Impact of capsule endoscopy findings in the management of Crohn’s disease. *Digestive Diseases and Sciences* 55(2): 411–414.

43. Long MD, Barnes E, Isaacs K et al. (2011) Impact of capsule endoscopy on management of inflammatory bowel disease: A single tertiary care center experience. *Inflammatory Bowel Diseases* 17(9): 1855–1862.

44. Kim Y, Jeon SR, Choi SM et al. (2017) Practice patterns and clinical significance of use of capsule endoscopy in suspected and established Crohn’s disease. *Intestinal Research* 15(4): 467–474.

45. Rosa B, Pinho R, de Ferro SM et al. (2015) Endoscopic scores for evaluation of Crohn’s disease activity at small bowel capsule endoscopy: General principles and current applications. *GE Portuguese Journal of Gastroenterology* 23(1): 36–41.

46. Koulaouzidis A, Douglas S and and Plevris JN (2012) Lewis score correlates more closely with fecal calprotectin than capsule endoscopy Crohn’s disease activity index. *Digestive Diseases and Sciences* 57(4): 987–993.

47. Nylund K, Hausken T and Gilja OH (2010) Ultrasound and inflammatory bowel disease. *Ultrasound Quarterly* 26(1): 3–15.

48. Ma X, Li Y, Jia H et al. (2015) Contrast-enhanced ultrasound in the diagnosis of patients suspected of having active Crohn’s disease: Meta-analysis. *Ultrasound in Medicine and Biology* 41(3): 659–668.

49. Pauls S, Gabelmann A, Schmidt SA et al. (2006) Evaluating bowel wall vascularity in Crohn’s disease: A comparison of dynamic MRI and wideband harmonic imaging contrast-enhanced low MI ultrasound. *European Radiology* 16(11): 2410–2417.

50. Ripollès T, Martinez MJ, Paredes JM et al. (2009) Small bowel capsule endoscopy: General principles and current applications. *GE Portuguese Journal of Gastroenterology* 23(1): 36–41.

51. Romanini L, Passamonti M, Navarra M et al. (2014) Quantitative analysis of contrast-enhanced ultrasoundography of the bowel wall can predict disease activity in inflammatory bowel disease. *European Journal of Radiology* 83(8): 1317–1323.

52. Quaia E, Migaleddu V, Baratella E et al. (2009) The diagnostic value of small bowel wall vascularity after sulfur hexafluoride-filled microbubble injection in patients with Crohn’s disease. Correlation with the therapeutic effectiveness of specific anti-inflammatory treatment. *European Journal of Radiology* 69(3): 438–444.

53. Saevik F, Nylund K, Hausken T et al. (2014) Bowel perfusion measured with dynamic contrast-enhanced
ultrasound predicts treatment outcome in patients with Crohn’s disease. Inflammatory Bowel Diseases 20(11): 2029–2037.

54. Paredes JM, Ripollés T, Cortés X et al. (2013) Contrast-enhanced ultrasonography: Usefulness in the assessment of postoperative recurrence of Crohn’s disease. Journal of Crohn’s and Colitis 7(3): 192–201.

55. Wu YW, Tang YH, Hao NX et al. (2012) Crohn’s disease: CT enterography manifestations before and after treatment. European Journal of Radiology 81(1): 52–59.

56. Minordi LM, Scaldaferr F, Larosa L et al. (2015) Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn’s disease: New prospective roles of CT enterography. Radiology Medicine 120(5): 449–457.

57. Fiorino G, Bonfaccio C, Peyrin-Biroulet L et al. (2011) Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease. Inflammatory Bowel Diseases 17(5): 1073–1080.

58. Sagami S, Kobayashi T, Kikkawa N et al. (2019) Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn’s disease. PLoS One. 14(2): e0212404.

59. Takenaka K, Ohtsuka K, Kitazume Y et al. (2018) Utility of magnetic resonance enterography for small bowel endoscopic healing in patients with Crohn’s disease. The American Journal of Gastroenterology 113(2): 283–294.

60. Gonczi L, Bessissow T and and Lakatos PL (2019) Ver(s)ifying the efficacy of Vedolizumab therapy on mucosal healing in patients with Crohn’s Disease. Gastroenterology 157(4): 925–927.

61. Cassinotti A, Keshav S, Ardizzzzone S et al. (2009) IBD care in Europe: A comparative audit of the inpatient management of Crohn’s disease and ulcerative colitis using the national UK IBD audit tool. Journal of Crohn’s and Colitis 3(4): 291–301.

62. Johnson SL, Bartels CM, Palta M et al. (2015) Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: a US Medicare cohort study. BMJ Open 5(9): e008597.

63. Lichtenstein GR, Feagan BG, Cohen RD et al. (2006) Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clinical Gastroenterology and Hepatology 4(5): 621–630.

64. Ezzat Y and Hamdy K (2010) The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. International Journal of Rheumatic Diseases 13(3): 259–265.

65. Steenholdt C, Brynskov J, Thomsen ØØ et al. (2014) Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut 63(6): 919–927.

66. Vande Casteele N, Ferrante M, Van Assche G et al. (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148(7): 1320–1329.

67. Kamperidis N, Middleton P, Tyrrell T et al. (2019) Impact of therapeutic drug level monitoring on outcomes of patients with Crohn’s disease treated with Infliximab: Real world data from a retrospective single centre cohort study. Frontline Gastroenterology 10(4): 330–336.

68. Seinen ML, De Boer NK and van Bodegraven AA (2019) Key insights from therapeutic drug monitoring in Crohn’s disease patients. Expert Opinion on Drug Metabolism & Toxicology 15(5): 399–406.

69. Dreesen E, Baert F, Laharie D et al. (2020) Monitoring a combination of calprotectin and infliximab identifies patients with mucosal healing of Crohn’s Disease. Clinical Gastroenterology and Hepatology 18(3): 637–646.

70. Roffman I, Sun YC, Fedwick JP et al. (2009) Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 7(2): 175–182.

71. Zezos P, Kouklakis G and Saibil F (2014) Inflammatory bowel disease and thromboembolism. World Journal of Gastroenterology 20(38): 13863–13878.

72. Fumery M, Xiaoacang C, Dauchet L et al. (2014) Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. Journal of Crohn’s and Colitis 8(6): 469–479.

73. Burisch J and and Munkholm P (2013) Inflammatory bowel disease epidemiology. Current Opinion in Gastroenterology 29(4): 357–362.

74. Walker BR (2007) Glucocorticoids and cardiovascular disease. European Journal of Endocrinology 157(5): 545–559.

75. Singh S, Nagpal SJ, Murad MH et al. (2014) Inflammatory bowel disease is associated with an increased risk of melanoma: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 12(2): 210–218.

76. Long MD, Martin CF, Pipkin CA et al. (2012) Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 143(2): 390–399.

77. Cullen G, Kroshinsky D, Cheifetz AS et al. (2011) Psoriasis associated with anti-tumour necrosis factor
therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature. *Alimentary Pharmacology & Therapeutics* 34(11–12): 1318–1327.

78. Pallotta N, Vincoli G, Pezzotti P et al. (2018) A risk score system to timely manage treatment in Crohn’s disease: A cohort study. *BMC Gastroenterology* 18(1): 164.

79. Bernstein CN, Blanchard JF, Rawsthorne P et al. (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. *The American Journal of Gastroenterology* 96(4): 1116–1122.

80. Harbord M, Annese V, Vavricka SR et al. (2016) The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. *Journal of Crohn’s and Colitis* 10(3): 239–254.

81. Zheng HH and and Jiang XL (2016) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: A meta-analysis of 16 observational studies. *European Journal of Gastroenterology & Hepatology* 28(4): 383–390.

82. Huang V, Mishra R, Thanabal R et al. (2013) Patient awareness of extraintestinal manifestations of inflammatory bowel disease. *Journal of Crohn’s and Colitis* 7(8): e318–e324.